CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
varenicline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00835900
NCT00835900Phase 2Completed
CompareCT.gov

Extended Varenicline for Smoking Cessation: A Pilot Study

Roswell Park Cancer Institute·interventional·Posted Feb 4, 2009·Updated May 30, 2017

In Brief

A Phase 2 clinical trial evaluating varenicline and placebo for Smoking Cessation. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2009
Enrollment StartMar 1, 2009
Primary CompletionJul 1, 2010
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.4 years ago

Interventions

vareniclinedrug

variable dosing schedule

placebodrug

placebo